ENGN earnings: next report 2026-09-14, real EPS beat/miss history, analyst consensus Hold, P/E -1.40. Updated 2026-07-23.
enGene Holdings (ENGN) Research Hub
enGene Holdings (ENGN) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.8 USD (-2.70%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.40, market cap 0.09B. This hub links to the full technical, earnings and options research available for ENGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 1.8 USD (-2.70%) |
| 52-week range | 1.68 USD – 1.96 USD |
| Trend regime | Range |
| 14-day RSI | 50 (Neutral) |
| Trailing P/E | -1.40 |
| Market cap | 0.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-14 |
Available research for ENGN
Covered Call on ENGN: how it works, illustrative setup around the real 1.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENGN: how it works, illustrative setup around the real 1.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENGN: how it works, illustrative setup around the real 1.8 USD price, max profit/loss, breakeven and when to use it. Educational.
ENGN technical analysis: range, last 1.8 USD, RSI 50, 52w range 1.68 USD–1.96 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ENGN in?
enGene Holdings (ENGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is ENGN in an uptrend or downtrend?
As of 2026-09-11, ENGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENGN's trailing P/E ratio?
ENGN's trailing P/E is -1.40, with a market cap of 0.09B. See the earnings research page for full valuation detail.
When does ENGN next report earnings?
ENGN is next scheduled to report earnings on 2026-09-14, with a consensus EPS estimate of -0.47 USD.